(Q43592410)

25 November 2017

title

An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation (English)

1 reference

25 November 2017

1 reference

D Polsky

1

1 reference

25 November 2017

K P Weinfurt

2

1 reference

25 November 2017

B Kaplan

3

1 reference

25 November 2017

J Kim

4

1 reference

25 November 2017

J Fastenau

5

1 reference

25 November 2017

K A Schulman

6

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Nephrology Dialysis Transplantation

25 November 2017

published in

1 reference

25 November 2017

volume

16

1 reference

25 November 2017

issue

5

1 reference

25 November 2017

page(s)

1028-1033

1 reference

Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F16.5.1028

A comparison of scoring weights for the EuroQol derived from patients and the general public.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F16.5.1028

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F16.5.1028

The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F16.5.1028

Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F16.5.1028

Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F16.5.1028

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F16.5.1028

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F16.5.1028

A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2F16.5.1028

21 January 2018

Identifiers

DOI

10.1093/NDT/16.5.1028

1 reference

25 November 2017

1 reference